References
- Drugs@FDA. Approval history, letters, review, and related documents on ponatinib. Available from: www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails [Last accessed 21 July 2014]
- Kurzrock R, Kantarjian HM, Druker BJ, Talpaz M. Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Ann Intern Med 2003;138(10):819-30
- Zhou T, Commodore L, Huang WS, et al. Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance. Chem Biol Drug Des 2011;77(1):1-11
- Hochhaus A, O’Brien SG, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009;23(6):1054-61
- Soverini S, De Benedittis C, Papayannidis C, et al. Drug resistance and BCR-ABL kinase domain mutations in philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: the main changes are in the type of mutations, but not in the frequency of mutation involvement. Cancer 2014;120(7):1002-9
- O’Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009;16(5):401-12
- Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 2012;367(22):2075-88
- Senior M. FDA halts then allows sales of Ariad’s leukemia medication. In: Nature Biotechnology. United States: 2014. pp 9-11
- Cortes JE, Kim DW, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 2013;369(19):1783-96
- Hochhaus A, Pinilla-Ibarz J, Kim D-W, et al. Clinical impact of dose modification and dose intensity on response to ponatinib on patients with Philadelphia chromosome-positive leukemias. J Clin Oncology 2014;32(5 suppl): abstr 7084
- Rix U, Colinge J, Blatt K, et al. A target-disease network model of second-generation BCR-ABL inhibitor action in Ph+ ALL. PLoS One 2013;8(10):e77155